Premium
Noncholestatic acute hepatocellular injury following candesartan administration
Author(s) -
LammelLindemann Jan Antonio,
FloresVillalba Eduardo,
Martagón Alexandro Jose,
DeObesoGonzalez Eduardo,
PuenteGallegos Francisco
Publication year - 2018
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13406
Subject(s) - candesartan , medicine , adverse effect , blood pressure , intensive care medicine , angiotensin ii , pharmacology
Arterial hypertension is a highly manageable disorder due to a variety of drugs available for its treatment. Since the late 1990s, angiotensin II receptor blockers have been widely prescribed, achieving appropriate control in patients’ blood pressure. Few cases of serious adverse effects have been reported to date. Here, we present a case of acute hepatocellular injury secondary to candesartan administration. Further studies should be performed in patients who present with this adverse effect, in order to prevent more serious outcomes.